Improving Patient Outcomes in IPF

Released On
July 14, 2021

Expires On
July 13, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Critical Care, Primary Care, Pulmonology

Topic(s)
Respiratory

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by The France Foundation.

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for pulmonologists, critical care specialists, internists, fellows, and other health care providers who manage patients with IPF.

Program Overview

This activity will cover Idiopathic Pulmonary Fibrosis.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Integrate new information on IPF treatment into practice as it becomes available
  • Discuss timing and rationale for starting antifibrotic therapy
  • Decide when to stop or switch treatment
  • Discuss disease progression treatment expectations and the importance of adhering to treatment

Faculty

FACULTY_NAME

Kevin Flaherty, MD

Director Interstitial Lung Disease Program
Professor of Medicine
University of Michigan

FACULTY_NAME

Lisa H. Lancaster, MD

Director Interstitial Lung Disease Program
Professor of Medicine
Vanderbilt University

 

Physician Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The faculty listed below report that they have relevant financial relationships to disclose:

Kevin Flaherty, MD

  • Contract Research: University of Michigan, Boehringer Ingelheim Pharmaceuticals, Inc.
  • Non-CE Research: Bellerophon, Blade Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Respivant, Vindico, Roche/Genentech, Shionogi.
  • Consulting: Arrowhead Pharmaceuticals, AstraZeneca, DevPro Biopharma, Fibrogen, Horizon, Lupin Pharmaceuticals, Pure Health, Sun Pharmaceutical, Pliant, Polarean, United Therapeutics.

Lisa H. Lancaster, MD

  • Consulting: AstraZeneca, Bellerophon, BMS, DevPro Biopharma, Galapagos, Genentech, Pliant, United Therapeutics, Veracyte.
  • Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, United Therapeutics, and Veracyte.
  • Contract Research: Biogen, Boehringer Ingelheim Pharmaceuticals, Inc., Bellerophon, BMS, Celgene, Fibrogen, Galecto, Galapagos, and Novartis, Pliant, Respivant, and Roche.

Instructions for Participation and Credit

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity
  4. Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

 

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.